Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival A Large Cohort Study of the German Network for Systemic Sclerosis

被引:8
|
作者
Moinzadeh, Pia [1 ]
Bonella, Francesco [2 ]
Oberste, Max [3 ]
Weliwitage, Jithmi [3 ]
Blank, Nobert [4 ]
Riemekasten, Gabriela [5 ]
Mueller-Ladner, Ulf [6 ]
Henes, Joerg [7 ]
Siegert, Elise [8 ,9 ]
Guenther, Claudia [10 ]
Koetter, Ina [11 ,12 ]
Pfeiffer, Christiane [13 ]
Schmalzing, Marc [14 ]
Zeidler, Gabriele [15 ]
Korsten, Peter [16 ]
Susok, Laura [17 ]
Juche, Aaron [18 ]
Worm, Margitta [19 ]
Jandova, Ilona [20 ]
Ehrchen, Jan [21 ]
Sunderkoetter, Cord [22 ]
Keysser, Gernot [23 ]
Ramming, Andreas [24 ,25 ]
Schmeiser, Tim [26 ]
Kreuter, Alexander [27 ]
Lorenz, Hanns-Martin [4 ]
Hunzelmann, Nicolas [1 ]
Kreuter, Michael [28 ,29 ]
机构
[1] Univ Hosp Cologne, Dept Dermatol & Venereol, Cologne, Germany
[2] Univ Duisburg Essen, Pneumonol Dept, Ctr Interstitial & Rare Lung Dis, Ruhrlandklin, Essen, Germany
[3] Univ Hosp Cologne, Inst Med Stat & Computat Biol, Fac Med, Cologne, Germany
[4] Univ Hosp Heidelberg, Div Rheumatol, Internal Med 5, Heidelberg, Germany
[5] Univ Lubeck, Univ Hosp Schleswig Holstein, Clin Rheumatol & Clin Immunol, D-23562 Lubeck, Germany
[6] Kerckhoff Clin & Fdn, Dept Rheumatol, D-61231 Bad Nauheim, Germany
[7] Univ Hosp Tubingen, Ctr Interdisciplinary Rheumatol Clin Immunol & Au, Tubingen, Germany
[8] Charite Univ Med Berlin, Dept Rheumatol & Clin Immunol, Berlin, Germany
[9] Berlin Inst Hlth, Berlin, Germany
[10] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Dermatol, Dresden, Germany
[11] Univ Hosp Hamburg Eppendorf, Div Rheumatol & Syst Inflammatory Dis, Hamburg, Germany
[12] Rheumatol Clin Bad Bramstedt, Bad Bramstedt, Germany
[13] Univ Med Ctr Ulm, Dept Dermatol & Allergol, Ulm, Germany
[14] Univ Hosp Wurzburg, Dept Internal Med 2, Rheumatol Clin Immunol, Wurzburg, Germany
[15] Johanniter Hosp Treuenbrietzen, Ctr Rheumatol Brandenburg, Dept Rheumatol Osteol & Pain Therapy, Treuenbrietzen, Germany
[16] Univ Med Ctr Gottingen, Dept Nephrol & Rheumatol, Gottingen, Germany
[17] St Josef Hosp, Dept Dermatol Venereol & Allergol, Bochum, Germany
[18] Immanuel Krankenhaus Berlin, Dept Rheumatol, D-13125 Berlin, Germany
[19] Charite Univ Med Berlin, Dept Dermatol Venereol & Allergol, DE-10117 Berlin, Germany
[20] Univ Med Ctr Freiburg, Rheumatol & Clin Immunol, Freiburg, Germany
[21] Univ Hosp Munster, Dept Dermatol, Munster, Germany
[22] Univ Hosp Halle Saale, Dept Dermatol, Halle, Saale, Germany
[23] Univ Hosp Halle Saale, Div Rheumatol, Internal Med, Halle, Saale, Germany
[24] Friedrich Alexander Univ FAU Erlangen Nurnberg, Dept Internal Med Rheumatol & Immunol 3, Erlangen, Germany
[25] Univ Hosp Erlangen, Erlangen, Germany
[26] Hosp St Josef, Internal Med Rhematol & Osteol, Wuppertal, Germany
[27] Univ Witten Herdecke, Helios St Elisabeth Hosp Oberhausen, Dept Dermatol Venereol & Allergol, Oberhausen, Germany
[28] Mainz Univ Med Ctr, Mainz Ctr Pulm Med, Dept Pneumol, Mainz, Germany
[29] Marienhaus Clin Mainz, Dept Pulm Crit Care & Sleep Med, Mainz, Germany
关键词
ILD; ILD-PH; ILD-w/o-PH; interstitial lung disease; overall survival; PAH; PH; pulmonary hypertension; scleroderma; SSc; survival; systemic sclerosis; ARTERIAL-HYPERTENSION; PREDICTING MORTALITY; SCLERODERMA; CLASSIFICATION; METAANALYSIS; PROGRESSION; MANAGEMENT; DIAGNOSIS; SUBSETS;
D O I
10.1016/j.chest.2023.08.013
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
BACKGROUND: Pulmonary involvement is the leading cause of death in systemic sclerosis (SSc) and may manifest as interstitial lung disease (ILD), pulmonary arterial hypertension (PAH), or in combination of both (ILD with pulmonary hypertension [ILD -PH]). The aim of this analysis was to determine prevalence, clinical characteristics, and survival of these different forms within the registry of the German Network for Systemic Sclerosis. RESEARCH QUESTION: Does SSc-associated ILD -PH or ILD without PH affect survival differently, and are there any risk factors that have an additional impact? STUDY DESIGN AND METHODS: Clinical data of 5,831 patients with SSc were collected in the German Network for Systemic Sclerosis registry. Kaplan -Meier estimates were used to compare overall survival in patients with SSc-associated ILD -PH and ILD without PH with patients without pulmonary involvement and those with PAH. The Cox proportional hazard model was used to analyze the influence of pulmonary involvement and other potential predictors on patient survival. RESULTS: Clinical data of 3,257 patients with a mean follow-up time of 3.45 +/- 1.63 years have been included in our analysis. At baseline, ILD was present in 34.5%, whereas PH without ILD had a lower prevalence with 4.5%. At the end of follow-up, 47.6% of patients with SSc had ILD, 15.2% had ILD -PH, and 6.5% had PAH. ILD was more frequent in the diffuse cutaneous form (57.3%), whereas PAH did not differ significantly between SSc subtypes. Significant differences in baseline characteristics between PAH vs ILD -PH vs ILD without PH were found for age at diagnosis, sex, SSc subsets, antibody status, FVC, diffusing capacity of the lung for carbon monoxide, and therapy. Overall survival at 5 years was 96.4% for patients without pulmonary involvement and differed significantly between patients with ILD without PH, PAH, and being worst in patients with ILD-PH. Female sex (hazard ratio [HR], 0.3), higher BMI (HR, 0.9), and higher diffusing capacity of the lung for carbon monoxide values (HR, 0.98) were associated with a lower mortality risk. INTERPRETATION: ILD is the most prevalent pulmonary involvement in SSc, whereas the combination of ILD and PH is associated with the most detrimental survival.
引用
收藏
页码:132 / 145
页数:14
相关论文
共 50 条
  • [21] Systemic Sclerosis-Associated Pulmonary Hypertension: Spectrum and Impact
    Naranjo, Mario
    Hassoun, Paul M.
    DIAGNOSTICS, 2021, 11 (05)
  • [22] Clinical characteristics and survival of pulmonary arterial hypertension with or without interstitial lung disease in systemic sclerosis
    Fairley, Jessica L.
    Hansen, Dylan
    Ross, Laura
    Proudman, Susanna
    Sahhar, Joanne
    Ngian, Gene-Siew
    Walker, Jennifer
    Host, Lauren, V
    Morrisroe, Kathleen
    Apostolopoulous, Diane
    Ferdowsi, Nava
    Wilson, Michelle
    Tabesh, Maryam
    Stevens, Wendy
    Nikpour, Mandana
    ARTHRITIS RESEARCH & THERAPY, 2023, 25 (01)
  • [23] Proteomic biomarkers for survival in systemic sclerosis-associated pulmonary hypertension
    Mismetti, Valentine
    Delavenne, Xavier
    Montani, David
    Bezzeghoud, Souad
    Delezay, Olivier
    Hodin, Sophie
    Launay, David
    Marchand-Adam, Sylvain
    Nunes, Hilario
    Ollier, Edouard
    Reynaud-Gaubert, Martine
    Pastre, Jean
    Traclet, Julie
    Quetant, Sebastien
    Zeghmar, Sabrina
    Bertoletti, Laurent
    Cottin, Vincent
    RESPIRATORY RESEARCH, 2023, 24 (01)
  • [24] Proteomic biomarkers for survival in systemic sclerosis-associated pulmonary hypertension
    Valentine Mismetti
    Xavier Delavenne
    David Montani
    Souad Bezzeghoud
    Olivier Delezay
    Sophie Hodin
    David Launay
    Sylvain Marchand-Adam
    Hilario Nunes
    Edouard Ollier
    Martine Reynaud-Gaubert
    Jean Pastre
    Julie Traclet
    Sébastien Quetant
    Sabrina Zeghmar
    Laurent Bertoletti
    Vincent Cottin
    Respiratory Research, 24
  • [25] Clinical characteristics and survival of pulmonary arterial hypertension with or without interstitial lung disease in systemic sclerosis
    Jessica L. Fairley
    Dylan Hansen
    Laura Ross
    Susanna Proudman
    Joanne Sahhar
    Gene-Siew Ngian
    Jennifer Walker
    Lauren V. Host
    Kathleen Morrisroe
    Diane Apostolopoulous
    Nava Ferdowsi
    Michelle Wilson
    Maryam Tabesh
    Wendy Stevens
    Mandana Nikpour
    Arthritis Research & Therapy, 25
  • [26] Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
    Chung, Jonathan H.
    Walker, Christopher M.
    Hobbs, Stephen
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2020, (160): : na
  • [27] Personalized Medicine for Systemic Sclerosis-Associated Interstitial Lung Disease
    Ma, Angela
    Montesi, Sydney B.
    CURRENT TREATMENT OPTIONS IN RHEUMATOLOGY, 2025, 11 (01)
  • [28] Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease REPLY
    Distler, Oliver
    Gahlemann, Martina
    Maher, Toby M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (16): : 1596 - 1597
  • [29] CHARACTERISTICS OF QUANTITATIVE CT ANALYSIS AND PULMONARY HYPERTENSION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE
    Jesudasen, Sirus
    Patel, Badar
    D'Silva, Kristin
    Nardelli, Pietro
    Estepar, Ruben San Jose
    Washko, George
    Estepar, Raul San Jose
    Rahaghi, Farbod
    Montesi, Sydney
    CHEST, 2021, 160 (04) : 2145A - 2146A
  • [30] Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease
    Athanasios Koutroumpas
    Athanasios Ziogas
    Ioannis Alexiou
    Georgia Barouta
    Lazaros I. Sakkas
    Clinical Rheumatology, 2010, 29 : 1167 - 1168